| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 24 | 2023 | 2545 | 2.000 |
Why?
|
| Drug Hypersensitivity | 4 | 2023 | 97 | 1.630 |
Why?
|
| Fever | 6 | 2020 | 306 | 1.600 |
Why?
|
| Antimicrobial Stewardship | 3 | 2022 | 87 | 1.480 |
Why?
|
| Typhus, Endemic Flea-Borne | 2 | 2020 | 28 | 1.200 |
Why?
|
| Gentamicins | 4 | 2018 | 86 | 1.200 |
Why?
|
| Candidemia | 4 | 2023 | 44 | 1.000 |
Why?
|
| Antifungal Agents | 6 | 2024 | 294 | 0.960 |
Why?
|
| Candidiasis, Invasive | 4 | 2024 | 23 | 0.930 |
Why?
|
| Candida | 3 | 2014 | 78 | 0.840 |
Why?
|
| Exanthema | 3 | 2020 | 71 | 0.830 |
Why?
|
| Fever of Unknown Origin | 2 | 2016 | 43 | 0.830 |
Why?
|
| Sepsis | 4 | 2023 | 494 | 0.830 |
Why?
|
| Metagenomics | 2 | 2022 | 115 | 0.820 |
Why?
|
| Outpatients | 3 | 2023 | 266 | 0.780 |
Why?
|
| Child | 38 | 2024 | 26172 | 0.740 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 323 | 0.730 |
Why?
|
| Blood Culture | 1 | 2022 | 35 | 0.720 |
Why?
|
| Enterobacter | 1 | 2021 | 13 | 0.710 |
Why?
|
| Meningitis | 2 | 2019 | 98 | 0.700 |
Why?
|
| Respiratory Tract Infections | 2 | 2023 | 292 | 0.690 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 57 | 0.680 |
Why?
|
| Pediatrics | 4 | 2020 | 1244 | 0.670 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 552 | 0.660 |
Why?
|
| Pneumonia | 2 | 2023 | 338 | 0.640 |
Why?
|
| Angiostrongylus cantonensis | 2 | 2018 | 8 | 0.640 |
Why?
|
| Strongylida Infections | 2 | 2018 | 14 | 0.640 |
Why?
|
| Bacteremia | 3 | 2021 | 425 | 0.630 |
Why?
|
| Child Health | 2 | 2024 | 66 | 0.620 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 915 | 0.610 |
Why?
|
| Rickettsia typhi | 1 | 2019 | 12 | 0.600 |
Why?
|
| Headache | 1 | 2019 | 108 | 0.570 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 2 | 0.570 |
Why?
|
| Infant | 20 | 2024 | 13285 | 0.560 |
Why?
|
| Leukemia | 1 | 2021 | 373 | 0.550 |
Why?
|
| Urinary Tract Infections | 3 | 2016 | 327 | 0.510 |
Why?
|
| Humans | 63 | 2024 | 130447 | 0.510 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 25 | 0.490 |
Why?
|
| Child, Preschool | 18 | 2024 | 14989 | 0.490 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 266 | 0.440 |
Why?
|
| Electronic Health Records | 1 | 2022 | 812 | 0.430 |
Why?
|
| Culturally Competent Care | 1 | 2015 | 50 | 0.430 |
Why?
|
| Penicillins | 4 | 2023 | 153 | 0.420 |
Why?
|
| Tropical Medicine | 1 | 2015 | 104 | 0.420 |
Why?
|
| Adolescent | 20 | 2024 | 20754 | 0.410 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 292 | 0.410 |
Why?
|
| Obesity | 2 | 2018 | 2380 | 0.400 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 2003 | 16 | 0.390 |
Why?
|
| Male | 31 | 2024 | 64550 | 0.380 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 226 | 0.370 |
Why?
|
| Neglected Diseases | 1 | 2015 | 152 | 0.370 |
Why?
|
| Amphotericin B | 1 | 2012 | 90 | 0.370 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 454 | 0.350 |
Why?
|
| Retrospective Studies | 17 | 2023 | 17652 | 0.350 |
Why?
|
| Cross Infection | 3 | 2021 | 332 | 0.340 |
Why?
|
| Serum | 1 | 2011 | 43 | 0.330 |
Why?
|
| Simplexvirus | 1 | 2011 | 103 | 0.330 |
Why?
|
| Herpes Simplex | 1 | 2011 | 57 | 0.320 |
Why?
|
| Global Health | 1 | 2015 | 626 | 0.320 |
Why?
|
| Cohort Studies | 9 | 2024 | 5076 | 0.310 |
Why?
|
| Neutropenia | 1 | 2011 | 203 | 0.310 |
Why?
|
| Female | 28 | 2024 | 70337 | 0.310 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 265 | 0.290 |
Why?
|
| Bacterial Infections | 3 | 2023 | 322 | 0.280 |
Why?
|
| Primary Health Care | 3 | 2023 | 769 | 0.270 |
Why?
|
| Inappropriate Prescribing | 2 | 2020 | 40 | 0.260 |
Why?
|
| Brucella melitensis | 1 | 2007 | 8 | 0.260 |
Why?
|
| Brucellosis | 1 | 2007 | 19 | 0.250 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 28 | 0.250 |
Why?
|
| Streptococcus agalactiae | 2 | 2005 | 102 | 0.250 |
Why?
|
| Fetal Diseases | 1 | 2011 | 457 | 0.250 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1892 | 0.240 |
Why?
|
| Cough | 1 | 2007 | 99 | 0.240 |
Why?
|
| Internship and Residency | 2 | 2018 | 1215 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 489 | 0.240 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 312 | 0.230 |
Why?
|
| Streptococcal Vaccines | 1 | 2004 | 18 | 0.210 |
Why?
|
| Enterobacteriaceae | 2 | 2014 | 41 | 0.210 |
Why?
|
| Osteomyelitis | 1 | 2007 | 210 | 0.210 |
Why?
|
| Enterococcus faecalis | 2 | 2014 | 50 | 0.210 |
Why?
|
| Vaccines, Conjugate | 1 | 2004 | 84 | 0.210 |
Why?
|
| Politics | 1 | 2024 | 59 | 0.210 |
Why?
|
| Texas | 4 | 2020 | 3632 | 0.200 |
Why?
|
| Risk Factors | 8 | 2023 | 10940 | 0.200 |
Why?
|
| Antibodies, Bacterial | 2 | 2005 | 412 | 0.190 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2014 | 175 | 0.190 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 34 | 0.190 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2003 | 77 | 0.180 |
Why?
|
| Philadelphia | 1 | 2022 | 29 | 0.180 |
Why?
|
| Cephalosporins | 2 | 2020 | 136 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2023 | 148 | 0.170 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 29 | 0.170 |
Why?
|
| Community-Acquired Infections | 1 | 2023 | 251 | 0.170 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 435 | 0.170 |
Why?
|
| Triazoles | 2 | 2024 | 138 | 0.160 |
Why?
|
| Skin Tests | 1 | 2021 | 95 | 0.160 |
Why?
|
| Prednisone | 2 | 2016 | 238 | 0.160 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 207 | 0.160 |
Why?
|
| Myalgia | 1 | 2020 | 9 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2023 | 221 | 0.160 |
Why?
|
| Disease Vectors | 1 | 2020 | 22 | 0.160 |
Why?
|
| Mycoses | 1 | 2021 | 108 | 0.160 |
Why?
|
| Immunization | 1 | 2021 | 265 | 0.160 |
Why?
|
| Curriculum | 2 | 2015 | 784 | 0.160 |
Why?
|
| Feedback | 1 | 2020 | 148 | 0.150 |
Why?
|
| Doxycycline | 1 | 2020 | 111 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2022 | 159 | 0.150 |
Why?
|
| Photophobia | 1 | 2019 | 8 | 0.150 |
Why?
|
| Teaching | 2 | 2012 | 198 | 0.150 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 562 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 310 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 97 | 0.130 |
Why?
|
| Teicoplanin | 1 | 2017 | 4 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2018 | 128 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2020 | 248 | 0.130 |
Why?
|
| Eye Hemorrhage | 1 | 2016 | 4 | 0.130 |
Why?
|
| Ecchymosis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 13 | 0.130 |
Why?
|
| Education, Medical | 2 | 2012 | 290 | 0.120 |
Why?
|
| Infant, Newborn | 9 | 2015 | 8529 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2023 | 493 | 0.120 |
Why?
|
| Conjunctival Diseases | 1 | 2016 | 31 | 0.120 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2011 | 384 | 0.120 |
Why?
|
| Macrolides | 1 | 2016 | 31 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 2016 | 95 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2018 | 316 | 0.120 |
Why?
|
| Program Evaluation | 2 | 2015 | 441 | 0.120 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 79 | 0.120 |
Why?
|
| Orbital Diseases | 1 | 2016 | 66 | 0.120 |
Why?
|
| Edema | 1 | 2016 | 139 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2016 | 107 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 96 | 0.110 |
Why?
|
| Rat-Bite Fever | 1 | 2014 | 4 | 0.110 |
Why?
|
| Streptobacillus | 1 | 2014 | 4 | 0.110 |
Why?
|
| Specialization | 1 | 2015 | 75 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2021 | 698 | 0.110 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 29 | 0.110 |
Why?
|
| Infant, Premature, Diseases | 2 | 2009 | 254 | 0.110 |
Why?
|
| HIV Infections | 1 | 2007 | 2013 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1617 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 770 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2011 | 806 | 0.110 |
Why?
|
| Coagulase | 2 | 2012 | 22 | 0.110 |
Why?
|
| Chemoprevention | 2 | 2011 | 49 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 982 | 0.100 |
Why?
|
| Arthralgia | 1 | 2014 | 79 | 0.100 |
Why?
|
| United States | 8 | 2024 | 11820 | 0.100 |
Why?
|
| Students, Medical | 1 | 2018 | 341 | 0.100 |
Why?
|
| Staphylococcus | 2 | 2012 | 68 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4001 | 0.100 |
Why?
|
| Critical Pathways | 1 | 2013 | 76 | 0.090 |
Why?
|
| Hypokalemia | 1 | 2012 | 40 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 115 | 0.090 |
Why?
|
| Equipment Contamination | 1 | 2012 | 39 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 296 | 0.090 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2012 | 41 | 0.090 |
Why?
|
| Appendicitis | 1 | 2013 | 132 | 0.090 |
Why?
|
| Culture Media | 1 | 2012 | 171 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2018 | 1047 | 0.090 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 169 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12869 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2012 | 341 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 938 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 142 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 392 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 424 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 132 | 0.080 |
Why?
|
| Infant, Premature | 3 | 2011 | 852 | 0.080 |
Why?
|
| Half-Life | 1 | 2010 | 150 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 9993 | 0.080 |
Why?
|
| Shoulder Joint | 1 | 2009 | 29 | 0.080 |
Why?
|
| Hip Joint | 1 | 2009 | 50 | 0.070 |
Why?
|
| Eye | 1 | 2011 | 220 | 0.070 |
Why?
|
| Medical Records | 1 | 2010 | 177 | 0.070 |
Why?
|
| Central Nervous System | 1 | 2011 | 277 | 0.070 |
Why?
|
| Animals | 3 | 2020 | 33924 | 0.070 |
Why?
|
| Arthritis, Infectious | 1 | 2009 | 66 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2009 | 139 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 729 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 379 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3389 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 472 | 0.070 |
Why?
|
| Clinical Medicine | 1 | 2008 | 20 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 543 | 0.070 |
Why?
|
| Adult | 4 | 2021 | 31131 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2009 | 293 | 0.060 |
Why?
|
| Elbow Joint | 1 | 2007 | 14 | 0.060 |
Why?
|
| Sternum | 1 | 2007 | 51 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2014 | 6420 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 134 | 0.060 |
Why?
|
| Pneumonia, Bacterial | 1 | 2007 | 79 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2017 | 319 | 0.060 |
Why?
|
| Streptococcal Infections | 2 | 2005 | 251 | 0.060 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2004 | 3 | 0.050 |
Why?
|
| Aging | 2 | 2010 | 1253 | 0.050 |
Why?
|
| Carrier State | 1 | 2005 | 80 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3845 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 6779 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2004 | 46 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 116 | 0.050 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2004 | 65 | 0.050 |
Why?
|
| Serotyping | 1 | 2004 | 172 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 167 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2004 | 164 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2004 | 155 | 0.050 |
Why?
|
| Incidence | 1 | 2011 | 3330 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 319 | 0.050 |
Why?
|
| Pneumocystis | 1 | 2002 | 9 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 43 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 146 | 0.050 |
Why?
|
| Infectious Disease Medicine | 1 | 2022 | 13 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 158 | 0.040 |
Why?
|
| Aspirin | 1 | 2003 | 215 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2023 | 266 | 0.040 |
Why?
|
| Time Factors | 1 | 2011 | 6187 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 479 | 0.040 |
Why?
|
| Health Promotion | 1 | 2024 | 407 | 0.040 |
Why?
|
| Prevalence | 2 | 2023 | 2684 | 0.040 |
Why?
|
| Models, Econometric | 2 | 2011 | 8 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1627 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 528 | 0.040 |
Why?
|
| Palivizumab | 2 | 2011 | 48 | 0.040 |
Why?
|
| Patient Safety | 2 | 2016 | 440 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 1164 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 551 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1237 | 0.040 |
Why?
|
| Research | 1 | 2020 | 264 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1800 | 0.040 |
Why?
|
| Pregnancy | 1 | 2011 | 7429 | 0.030 |
Why?
|
| Hospitals | 1 | 2020 | 436 | 0.030 |
Why?
|
| Neoplasms | 1 | 2011 | 2944 | 0.030 |
Why?
|
| Vaccination | 1 | 2021 | 1040 | 0.030 |
Why?
|
| Dried Blood Spot Testing | 1 | 2016 | 27 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 3801 | 0.030 |
Why?
|
| Logic | 1 | 2015 | 10 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2567 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 566 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2112 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2018 | 279 | 0.030 |
Why?
|
| Aged | 3 | 2018 | 20888 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 77 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 3034 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 680 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1680 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 677 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 3684 | 0.030 |
Why?
|
| Prognosis | 1 | 2003 | 4902 | 0.030 |
Why?
|
| Government Regulation | 1 | 2013 | 43 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2012 | 18 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 40 | 0.020 |
Why?
|
| Appendectomy | 1 | 2013 | 88 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 178 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 116 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 95 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 156 | 0.020 |
Why?
|
| Infection Control | 1 | 2013 | 160 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 366 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 193 | 0.020 |
Why?
|
| Health Policy | 1 | 2013 | 223 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 838 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 265 | 0.020 |
Why?
|
| Budgets | 1 | 2011 | 15 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 288 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1927 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 561 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1482 | 0.020 |
Why?
|
| Drainage | 1 | 2009 | 248 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 700 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 1394 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 544 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1292 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 660 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 54 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 210 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 204 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 148 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2004 | 168 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 598 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 247 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 182 | 0.010 |
Why?
|
| Vancomycin | 1 | 2004 | 221 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 790 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1378 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3106 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 1223 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 28376 | 0.010 |
Why?
|